发明名称 Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
摘要 Disclosed is a fusion protein having a prolonged half-life in vivo in comparison to naturally occurring or recombinant native human erythropoietin comprising: (a) a naturally occurring human erythropoietin molecule having a cysteine residue proximate to a C terminal thereof; and (b) a human IgG Fc fragment comprising a hinge region, wherein the N terminal of said Fc fragment is linked to said C terminal of said erythropoietin molecule and wherein said Fc fragment is naturally occurring except for a mutation replacing a cysteine residue of said hinge region located nearest said erythropoietin molecule with a non-cysteine residue, whereby the first cysteine residue of said hinge region located nearest said N terminal is spaced at least 17 amino acids apart from said cysteine residue of said erythropoietin molecule.
申请公布号 NZ569702(A) 申请公布日期 2012.03.30
申请号 NZ20070569702 申请日期 2007.01.25
申请人 NOVAGEN HOLDING CORPORATION 发明人 WANG, HAITAO;DU, YONG;ZHANG, RUI;XU, JING;LIU, LONGBIN
分类号 C07K14/505;A61K38/18;A61K47/42;A61K47/48;A61P7/00;C07K16/18;C07K19/00;C12N15/13;C12N15/18;C12N15/62;C12P21/02 主分类号 C07K14/505
代理机构 代理人
主权项
地址